An innovative therapy for secondary prevention after stroke has demonstrated effectiveness in an international study with over 12,000 patients. Here’s how it works and what changes for prevention
After a ischemic strokethe greatest fear for those who survive is only one: that it happens again. There stroke recurrence in fact, it represents one of the most concrete risks in the months and years following the first event, with often even more serious consequences. Today, however, international research opens up a new scenario in the secondary prevention of stroke. An experimental drug, asundexianhas been shown to reduce the risk of a second ischemic stroke by 26% without significantly increasing the danger of major bleeding. The results come from the large phase III OCEANIC-STROKE study, presented at the 2026 International Stroke Conference and published on New England Journal of Medicine. News that could change therapeutic strategies for millions of patients around the world.
How asundexian works: innovation in secondary prevention
The key to this new one therapeutic strategy it is the targeted modulation of coagulation, without excessively compromising the blood’s ability to clot. Unlike traditional anticoagulants, inhibitors of Factor XIa like asundexian are designed to reduce the risk of formation of pathological thrombi keeping the risk of serious bleeding low: a therapeutic balance long sought after in post-stroke management. Second Mike Sharmaneurologist and principal investigator of the trial, asundexian has demonstrated the ability to lower the probability of relapse already in the early stages of treatment and to maintain the effect over timewith benefits observed in different subgroups of patients regardless of age, gender or severity of the initial event. This represents a step forward compared to currently available therapies for secondary prevention of strokewhere the combination of antiplatelet or anticoagulant drugs is not always sufficient to guarantee risk-free protection.
Clinical implications and future of relapse prevention
Data from the OCEANIC-STROKE trial could influence future guidelines for post-ischemic stroke managementproposing the selective inhibition of Factor XIa as a new frontier for the prevention of relapses. At the moment, primary and secondary prevention strategies already include the use of antiplateletsblood pressure control, statins, and lifestyle modifications to reduce the overall risk of cerebrovascular events. The approach with asundexian therefore opens a new pharmacological path which, if confirmed by further analyzes and clinical implementations, could translate into a concrete benefit for millions of patients who survive a first stroke and they risk one relapse. However, as always in medicine, long-term follow-ups and real-world studies will be necessary to fully understand the benefits and limitations of this innovative therapy.
